Sex Differences in Ketamine Treatment Response: Hormonal and Genetic Factors

Evidence for sex differences in ketamine treatment response hormonal and genetic factors is strongest in animal research and remains limited in people. Female rodents often show antidepressant-like responses at lower ketamine doses than male rodents, but clinical studies have not established sex-specific dosing, menstrual-cycle scheduling, or genetic testing as standard care. For patients, the practical takeaway is to discuss hormones, current medicines, side effects, and treatment history with the prescribing clinician rather than changing dose or timing independently.

Ketamine is an NMDA receptor antagonist used in some supervised depression treatment settings. Biological sex refers to biological attributes such as chromosomes, hormones, and reproductive anatomy, while gender can also shape health experiences and access to care. Many ketamine studies report sex incompletely and do not have enough participants to test sex-related differences reliably.

What the evidence shows

Animal studies provide the clearest signal. A review by Carrier and Bhatt described sex-dependent antidepressant-like effects of ketamine in rodents, including studies in which female animals responded at lower doses than males. Franceschelli and colleagues reported behavioral effects in female mice at 3 mg/kg, while higher doses were needed in male mice in that experimental context. These findings are useful for generating clinical questions, but animal behavioral models cannot establish the dose a person should receive.

Human studies are less consistent. A post-hoc analysis of National Institute of Mental Health ketamine trial data reported no statistically significant sex difference in acute antidepressant response after a single infusion, although smaller analyses may not be able to detect subgroup effects. A systematic review of ketamine pharmacology and clinical use is available through PubMed, and readers can find broader context in our ketamine research and evidence guide.

According to the National Institute of Mental Health, major depression is more prevalent among adult women than adult men in the United States, a difference that makes careful sex- and gender-aware research important without proving that ketamine works differently for every individual.

Why hormones are being studied

Estrogen, progesterone, and the neurosteroid allopregnanolone can affect glutamate and GABA signaling, systems relevant to ketamine’s proposed antidepressant mechanisms. Estrogen has been studied for its effects on NMDA receptor expression and synaptic plasticity. Progesterone-derived allopregnanolone is a positive allosteric modulator of GABA-A receptors, meaning it can change inhibitory signaling in the brain.

These mechanisms support a research hypothesis that menstrual-cycle phase, perimenopause, menopause, pregnancy, or hormone treatment could affect ketamine response or side effects. They do not yet show that one cycle phase is best for treatment. The proposed periovulatory advantage described in preclinical reasoning has not been confirmed in prospective clinical trials.

Pregnancy and lactation require separate clinical consideration because the evidence base and risk-benefit discussion differ. See our guide to ketamine pregnancy and lactation considerations for questions to raise with a qualified clinician.

Pharmacokinetics and side effects

Pharmacokinetics describes how the body absorbs, distributes, metabolizes, and clears a medicine. Ketamine metabolism involves several enzymes, including CYP3A4, and enzyme activity can vary among people for many reasons, including other medicines, age, liver function, and hormones. This variability may affect exposure, but it does not justify assuming that all women or all men need a different dose.

Some studies have reported differences in dissociation ratings between groups, but the clinical findings are not uniform. Dissociation, blood pressure changes, nausea, and other effects should be tracked during supervised treatment. Readers considering risk factors can review ketamine safety and side effects and potential ketamine drug interactions.

Genetic factors: plausible, not ready for routine use

Researchers are studying genes involved in glutamate signaling and synaptic plasticity for clues about ketamine response. GRIA3, an X-linked gene, encodes an AMPA receptor subunit. AMPA receptor signaling is considered part of ketamine’s downstream antidepressant pathway, but a sex-linked GRIA3 effect on treatment response has not been established.

BDNF is another candidate because it supports synaptic plasticity. The BDNF Val66Met variant has been associated with altered ketamine response in some research samples, including a report by Laje and colleagues, but the evidence does not support using this variant alone to predict whether a person will benefit. The National Center for Biotechnology Information provides a reference record for BDNF rs6265 (Val66Met).

Genetics may eventually help refine treatment selection, but it should be viewed as one research area among clinical history, diagnosis, co-occurring conditions, medication use, and monitored treatment response.

Questions to discuss with a clinician

A useful treatment conversation includes whether symptoms or side effects seem to vary with hormonal changes, whether there have been changes in contraception or hormone therapy, and which prescribed or nonprescription medicines may affect ketamine safety. Ask how response and dissociation will be measured over time, what monitoring is planned, and when the treatment plan would be reassessed. For a broader overview of individualized considerations, see ketamine patient considerations.

What research still needs to answer

Prospective trials need to report sex-stratified outcomes, collect relevant hormone and menstrual-cycle information when appropriate, and be powered to test whether observed differences are clinically meaningful. Studies also need to separate biological sex effects from age, reproductive stage, body composition, medication use, and social factors that can influence outcomes. Until then, the most accurate conclusion is that sex-related biology is a credible research question, not a settled dosing framework.